01

Nemolizumab Phase II Shows Lasting Relief in Children's Atopic Dermatitis

Phase II data presented at PeDRA 2026 show nemolizumab delivered long-term symptom relief in children aged 2 to 11 with moderate-to-severe atopic dermatitis.